Nidan Laboratories & Healthcare Ltd (NIDAN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003561,
    "name": "Nidan Laborator.",
    "stock_name": "Nidan Laborator.",
    "full_name": "Nidan Laboratories & Healthcare Ltd",
    "name_url": "stocks-analysis/nidan-laborator",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.20",
    "chg": 0.15,
    "chgp": "0.75%",
    "dir": 1,
    "prev_price": "20.05",
    "mcapval": "28.08 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "NIDAN",
    "ind_name": "Hospital",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE0J6L01013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 5000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nidan-laborator-1003561-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nidan Laboratories & Healthcare: Valuation Metrics Reflect Shift in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-valuation-shifts-signal-changing-market-sentiment-3737472",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NidanLaboratori_valuationdot_3737472.png",
        "date": "2025-12-01 08:02:25",
        "description": "Nidan Laboratories & Healthcare has experienced a notable revision in its valuation parameters, with key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV) indicating a shift from previously attractive levels to a more moderate assessment. This article examines these changes in the context of the hospital sector and peer comparisons, providing insight into the stock’s current market positioning."
      },
      {
        "title": "Nidan Laboratories & Healthcare Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-hits-upper-circuit-amid-strong-buying-pressure-3735490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_stocks_hitting_upper_circuit_3735490.png",
        "date": "2025-11-28 11:00:11",
        "description": "Nidan Laboratories & Healthcare Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit of 13.68% and closing at ₹21.60. This sharp movement reflects robust buying interest and a notable outperformance relative to its sector and broader market indices."
      },
      {
        "title": "Nidan Laboratories & Healthcare Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-surges-1974-on-unprecedented-buying-interest-amid-upper-circuit-lock-3735405",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_only_buyers_3735405.png",
        "date": "2025-11-28 10:20:41",
        "description": "Nidan Laboratories & Healthcare Ltd has witnessed extraordinary buying momentum, registering a remarkable 19.74% gain in a single trading session. The stock has hit the upper circuit with only buy orders in the queue, signalling intense demand and a potential multi-day circuit scenario as sellers remain absent from the market."
      },
      {
        "title": "How has been the historical performance of Nidan Laborator.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-nidan-laborator-3694313",
        "imagepath": "",
        "date": "2025-11-12 23:34:03",
        "description": "Answer:\nThe historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year.\n\nBreakdown:\nNidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negat..."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3687842",
        "imagepath": "",
        "date": "2025-11-11 08:14:39",
        "description": "As of 10 November 2025, the valuation grade for Nidan Laborator. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 14.25, an EV to EBITDA of 7.38, and a Price to Book Value of 0.41, all of which suggest that the stock is trading at a discount compared to its intrinsic value.\n\nIn comparison with its peers, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 88.71, and also offers a more favorable EV to EBITDA ratio compared to Apollo Hospitals at 28.24. Despite recent underperformance relative to the Sensex, with a year-to-date return of -29.64% against the Sensex's 8.16%, the attractive valuation metrics suggest that Nidan Laborator. may present a compelling investment opportunity moving forward...."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3684266",
        "imagepath": "",
        "date": "2025-11-10 08:14:49",
        "description": "As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be significantly overvalued compared to its peers.\n\nIn comparison to its industry peers, Nidan Laborator. has a lower PE ratio than Apollo Hospitals, which stands at 65.65, and a more favorable EV to EBITDA ratio compared to Max Healthcare at 56.83. However, the company's return metrics, such as a ROCE of 3.44% and ROE of 2.90%, highlight its struggles in generating returns relative to its equity. Additionally, Nidan Laborator. has underperformed against the Sensex over the past year, with a stock return of -34.69% compared to the Sensex's 5.34%, reinforc..."
      },
      {
        "title": "Nidan Laboratories Adjusts Valuation Grade Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcares-valuation-grade-downgraded-from-attractive-to-fair-3684398",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_valuationdot_3684398.png",
        "date": "2025-11-10 08:02:31",
        "description": "Nidan Laboratories & Healthcare has adjusted its valuation, with a P/E ratio of 14.67 and a low price-to-book value of 0.43. Key metrics include an enterprise value to EBITDA ratio of 7.55 and a ROCE of 3.44%. The company maintains a modest valuation compared to peers amid market challenges."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3682966",
        "imagepath": "",
        "date": "2025-11-09 08:11:53",
        "description": "As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived investment quality. The company is currently fairly valued based on its financial metrics, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be overvalued in comparison to its peers.\n\nIn the peer comparison, Nidan Laborator. stands out against competitors such as Apollo Hospitals, which has a significantly higher PE ratio of 65.65, and Narayana Hrudaya, valued at 46.53. This contrast highlights Nidan's more attractive valuation relative to its peers, despite its own fair rating. Additionally, Nidan's recent stock performance has been notably poor, with a year-to-date return of -27.56%, compared to a Sensex return of 7.81%, further emphasizing the cha..."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3681953",
        "imagepath": "",
        "date": "2025-11-08 08:11:50",
        "description": "As of 7 November 2025, Nidan Laborator. has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43, which indicate a moderate valuation compared to its peers.\n\nIn comparison to its industry peers, Nidan Laborator. stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 65.65, and also lower than Narayana Hrudaya at 46.53. Despite the fair valuation, the company's return performance has been underwhelming, with a year-to-date decline of 27.56% compared to a 7.81% increase in the Sensex, suggesting potential concerns about its market position and growth prospects...."
      }
    ],
    "total": 87,
    "sid": "1003561",
    "stock_news_url": "https://www.marketsmojo.com/news/nidan-laboratories-healthcare-1003561"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nidan Laboratories & Healthcare: Valuation Metrics Reflect Shift in Market Assessment

2025-12-01 08:02:25

Nidan Laboratories & Healthcare has experienced a notable revision in its valuation parameters, with key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV) indicating a shift from previously attractive levels to a more moderate assessment. This article examines these changes in the context of the hospital sector and peer comparisons, providing insight into the stock’s current market positioning.

Nidan Laboratories & Healthcare Hits Upper Circuit Amid Strong Buying Pressure

2025-11-28 11:00:11

Nidan Laboratories & Healthcare Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit of 13.68% and closing at ₹21.60. This sharp movement reflects robust buying interest and a notable outperformance relative to its sector and broader market indices.

Nidan Laboratories & Healthcare Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-28 10:20:41

Nidan Laboratories & Healthcare Ltd has witnessed extraordinary buying momentum, registering a remarkable 19.74% gain in a single trading session. The stock has hit the upper circuit with only buy orders in the queue, signalling intense demand and a potential multi-day circuit scenario as sellers remain absent from the market.

How has been the historical performance of Nidan Laborator.?

2025-11-12 23:34:03

Answer: The historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year. Breakdown: Nidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negat...

Is Nidan Laborator. overvalued or undervalued?

2025-11-11 08:14:39

As of 10 November 2025, the valuation grade for Nidan Laborator. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 14.25, an EV to EBITDA of 7.38, and a Price to Book Value of 0.41, all of which suggest that the stock is trading at a discount compared to its intrinsic value. In comparison with its peers, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 88.71, and also offers a more favorable EV to EBITDA ratio compared to Apollo Hospitals at 28.24. Despite recent underperformance relative to the Sensex, with a year-to-date return of -29.64% against the Sensex's 8.16%, the attractive valuation metrics suggest that Nidan Laborator. may present a compelling investment opportunity moving forward....

Is Nidan Laborator. overvalued or undervalued?

2025-11-10 08:14:49

As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be significantly overvalued compared to its peers. In comparison to its industry peers, Nidan Laborator. has a lower PE ratio than Apollo Hospitals, which stands at 65.65, and a more favorable EV to EBITDA ratio compared to Max Healthcare at 56.83. However, the company's return metrics, such as a ROCE of 3.44% and ROE of 2.90%, highlight its struggles in generating returns relative to its equity. Additionally, Nidan Laborator. has underperformed against the Sensex over the past year, with a stock return of -34.69% compared to the Sensex's 5.34%, reinforc...

Nidan Laboratories Adjusts Valuation Grade Amidst Competitive Market Landscape

2025-11-10 08:02:31

Nidan Laboratories & Healthcare has adjusted its valuation, with a P/E ratio of 14.67 and a low price-to-book value of 0.43. Key metrics include an enterprise value to EBITDA ratio of 7.55 and a ROCE of 3.44%. The company maintains a modest valuation compared to peers amid market challenges.

Is Nidan Laborator. overvalued or undervalued?

2025-11-09 08:11:53

As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived investment quality. The company is currently fairly valued based on its financial metrics, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be overvalued in comparison to its peers. In the peer comparison, Nidan Laborator. stands out against competitors such as Apollo Hospitals, which has a significantly higher PE ratio of 65.65, and Narayana Hrudaya, valued at 46.53. This contrast highlights Nidan's more attractive valuation relative to its peers, despite its own fair rating. Additionally, Nidan's recent stock performance has been notably poor, with a year-to-date return of -27.56%, compared to a Sensex return of 7.81%, further emphasizing the cha...

Is Nidan Laborator. overvalued or undervalued?

2025-11-08 08:11:50

As of 7 November 2025, Nidan Laborator. has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43, which indicate a moderate valuation compared to its peers. In comparison to its industry peers, Nidan Laborator. stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 65.65, and also lower than Narayana Hrudaya at 46.53. Despite the fair valuation, the company's return performance has been underwhelming, with a year-to-date decline of 27.56% compared to a 7.81% increase in the Sensex, suggesting potential concerns about its market position and growth prospects....

View All News